Alendronate and dental implant healing

Implant success depends on osseointegration: bone growing into the surface of the titanium implant. This requires active bone remodeling, the same process bisphosphonates slow down. The intuition is that bisphosphonates would impair osseointegration, but the clinical reality is more nuanced. Current American Dental Association guidance does not consider osteoporosis-dose oral bisphosphonate therapy a contraindication to dental implants, though larger and longer-term comparative studies are still needed to establish how implants perform relative to unexposed patients.

The bigger concern is MRONJ (medication-related osteonecrosis of the jaw). The risk is concentrated at surgical trauma sites, which includes implant placement. For patients on osteoporosis-dose oral alendronate the absolute risk is very low — well under 1 percent — and longer exposure may add to that risk without there being a single duration cutoff. For patients on IV bisphosphonates used in cancer treatment the risk is meaningfully higher and changes how dental surgery is planned.

The risk profile also depends on the implant site, the surgical technique (more invasive placement raises risk), and other factors like steroid use, smoking, and diabetes. A patient on long-term oral alendronate with no other risk factors is a different conversation than the same patient with multiple risk factors stacked.